Bruce E. Sands
Impact in
- Genetics top 0.01%
- Inflammatory Bowel Disease
- Gastroenterology top 0.1%
Papers in
- Genetics 482
- Inflammatory Bowel Disease 477
- Chronic Lymphocytic Leukemia Research 27
- Epidemiology 216
- Microscopic Colitis 192
- Co-authors
- William J. Sandborn (184 shared papers)Brian G. Feagan (135 shared papers)Jean‐Frédéric Colombel (83 shared papers)Paul Rutgeerts (28 shared papers)Stephen B. Hanauer (18 shared papers)Gary R. Lichtenstein (16 shared papers)Silvio Danese (129 shared papers)Walter Reinisch (33 shared papers)
- Journals
- Gastroenterology (160 papers)The American Journal of Gastroenterology (95 papers)Inflammatory Bowel Diseases (79 papers)Journal of Crohn s and Colitis (77 papers)Clinical Gastroenterology and Hepatology (29 papers)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Bruce E. Sands
557 papers receiving 40.4k citations
Bruce E. Sands's Hit Papers
Peers
Comparison fields: 5 of 168
- Genetics 26.9k
- Gastroenterology 2.0k
- Epidemiology 11.4k
- Immunology 7.0k
- Hematology 1.7k
Countries citing papers authored by Bruce E. Sands
This map shows the geographic impact of Bruce E. Sands's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce E. Sands with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce E. Sands more than expected).
Fields of papers citing papers by Bruce E. Sands
This network shows the impact of papers produced by Bruce E. Sands. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce E. Sands. The network helps show where Bruce E. Sands may publish in the future.
Co-authors
The 25 scholars most cited alongside Bruce E. Sands, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 611 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2005 | 3017 |
| 2 | Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2013 | 2133 |
| 3 | Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment Hit paper breakdown → | 2012 | 2123 |
| 4 | Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease Hit paper breakdown → | 1999 | 2112 |
| 5 | Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease Hit paper breakdown → | 2013 | 2092 |
| 6 | Infliximab Maintenance Therapy for Fistulizing Crohn's Disease Hit paper breakdown → | 2004 | 1686 |
| 7 | STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD Hit paper breakdown → | 2021 | 1633 |
| 8 | Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2017 | 1274 |
| 9 | Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Hit paper breakdown → | 2012 | 1200 |
| 10 | ACG Clinical Guideline: Management of Crohn's Disease in Adults Hit paper breakdown → | 2018 | 960 |
| 11 | Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease Hit paper breakdown → | 2012 | 868 |
| 12 | Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2019 | 826 |
| 13 | Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis Hit paper breakdown → | 2011 | 711 |
| 14 | The safety of vedolizumab for ulcerative colitis and Crohn's disease Hit paper breakdown → | 2016 | 588 |
| 15 | Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed Hit paper breakdown → | 2014 | 549 |
| 16 | Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Hit paper breakdown → | 2019 | 486 |
| 17 | 2005 | 461 | |
| 18 | Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Hit paper breakdown → | 2011 | 456 |
| 19 | 2009 | 407 | |
| 20 | 2009 | 365 |
About Bruce E. Sands
Bruce E. Sands is a scholar working on Genetics, Epidemiology, Surgery, Immunology and Gastroenterology, having authored 611 papers that have together received 41.5k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (477 papers), Microscopic Colitis (192 papers), Eosinophilic Esophagitis (66 papers), Immunodeficiency and Autoimmune Disorders (42 papers), Biosimilars and Bioanalytical Methods (30 papers), Helicobacter pylori-related gastroenterology studies (29 papers), Chronic Lymphocytic Leukemia Research (27 papers) and Celiac Disease Research and Management (25 papers). The work is most often cited by research in Genetics (26.9k citations), Gastroenterology (2.0k citations), Epidemiology (11.4k citations), Immunology (7.0k citations) and Hematology (1.7k citations). Bruce E. Sands has collaborated with scholars based in United States, Canada and France. Frequent co-authors include William J. Sandborn, Brian G. Feagan, Jean‐Frédéric Colombel, Paul Rutgeerts, Stephen B. Hanauer, Gary R. Lichtenstein, Silvio Danese, Walter Reinisch, Daniel H. Present and Joshua R. Korzenik. Their work appears in journals such as Gastroenterology, The American Journal of Gastroenterology, Inflammatory Bowel Diseases, Journal of Crohn s and Colitis and Clinical Gastroenterology and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.